CoreFirst Bank & Trust Cuts Holdings in Eli Lilly and Company (NYSE:LLY)

CoreFirst Bank & Trust cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,000 shares of the company’s stock after selling 200 shares during the period. CoreFirst Bank & Trust’s holdings in Eli Lilly and Company were worth $583,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Lipe & Dalton purchased a new stake in Eli Lilly and Company during the 4th quarter worth $26,000. Core Wealth Advisors Inc. grew its position in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares in the last quarter. Tidemark LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $29,000. Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $37,000. Finally, Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $36,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now directly owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 567,826 shares of company stock valued at $475,376,178 in the last three months. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

LLY opened at $885.01 on Tuesday. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $892.20. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The business has a 50 day moving average price of $788.10 and a two-hundred day moving average price of $721.39. The company has a market capitalization of $841.12 billion, a price-to-earnings ratio of 130.34, a price-to-earnings-growth ratio of 1.92 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.62 earnings per share. Research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.59%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Citigroup raised their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group lifted their target price on Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $787.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.